Immunologic resolution of human chronic graft-versus-host disease.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  T. Triche,et al.  T lymphocyte abnormalities in juvenile systemic sclerosis patients. , 2013, Clinical immunology.

[4]  H. Döhner,et al.  T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naïve T cells , 2013, Haematologica.

[5]  G. Holländer,et al.  Epithelial cytoprotection sustains ectopic expression of tissue-restricted antigens in the thymus during murine acute GVHD. , 2013, Blood.

[6]  Keiji Tanaka,et al.  Aire-expressing thymic medullary epithelial cells originate from β5t-expressing progenitor cells , 2013, Proceedings of the National Academy of Sciences.

[7]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[8]  S. Sakaguchi,et al.  Development and maintenance of regulatory T cells. , 2013, Immunity.

[9]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[10]  A. Hess.  Equal opportunity targeting in chronic GVHD. , 2012, Blood.

[11]  J. Piette,et al.  Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions , 2012, Annals of the rheumatic diseases.

[12]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[13]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[14]  R. Storb,et al.  Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age , 2011, Haematologica.

[15]  J. Ritz,et al.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.

[16]  L. Klein,et al.  Antigen presentation in the thymus for positive selection and central tolerance induction , 2009, Nature Reviews Immunology.

[17]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[18]  S. Emerson,et al.  CD4+ T Cells Generated De Novo from Donor Hemopoietic Stem Cells Mediate the Evolution from Acute to Chronic Graft-versus-Host Disease1 , 2007, The Journal of Immunology.

[19]  A. Gudkov,et al.  Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. , 2007, Blood.

[20]  G. Holländer,et al.  Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. , 2007, Blood.

[21]  M. Tanimoto,et al.  Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. , 2007, Blood.

[22]  R. Negrin,et al.  Role of naturally arising regulatory T cells in hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  E. Montserrat,et al.  Clinical factors influencing T-cell receptor excision circle (TRECs) counts following allogeneic stem cell transplantation in adults. , 2006, Transplant immunology.

[24]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  R. Storb,et al.  Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.

[26]  B. Haynes,et al.  T-Cell recovery in adults and children following umbilical cord blood transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  R. Collins,et al.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[28]  R. Parkman.  Chronic graft‐versus-host disease , 1998, Current opinion in hematology.

[29]  C. Thoburn,et al.  Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. , 1997, Blood.

[30]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[31]  R. Parkman.  Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. , 1986, Journal of immunology.

[32]  R. Gale,et al.  Chronic graft versus host disease: a syndrome of disordered immunity. , 1979, The American journal of medicine.